

## Glaucoma Surgical Devices Sales Update 6 Months to 31 December 2022

- **Sales revenue of US\$5.7 million (A\$8.3 million) for the six months to 31 December 2022 based on unaudited results**
- **20% top line sales growth measured in constant currency, compared with the prior comparative period (PCP)**
- **28% sales growth measured in Australian dollars, compared with the PCP**
- **Sales growth underpinned by commercial launch of the new iTrack™ Advance canaloplasty device in key markets outside of the U.S. and China**
- **Strong sales performance of the original iTrack™ canaloplasty device in China**

Nova Eye Medical Limited (ASX: EYE) (**Nova Eye Medical** or the **Company**), a medical technology company committed to advanced ophthalmic treatment technologies and devices, today announces that it expects to report global sales of US\$5.7 million (A\$8.3 million) for the Company's glaucoma surgical devices segment for the six months to 31 December 2022. These results are subject to audit.

The Company's strong performance during the period was driven by the commercial launch of the new iTrack™ Advance canaloplasty device in select markets outside of the U.S. and China from June 2022 onwards, and via the sustained sales performance of the Company's original iTrack™ canaloplasty product in the U.S. Sales of the Company's iTrack™ canaloplasty product in China were also strong during the period. Total global sales revenue increased 20% in constant currency to reach US\$5.7 million during the period, compared to the PCP.

### **Nova Eye Medical Managing Director, Tom Spurling, commented:**

"We are pleased to report growth in sales for our glaucoma surgical devices segment. This solid performance was underpinned by the launch of our new iTrack™ Advance canaloplasty product in Europe and Canada and our continuing efforts to drive market awareness of our original iTrack™ canaloplasty product in the USA and China."

"In Germany, our direct sales team made good progress in its efforts to target glaucoma surgeons to support our initial launch efforts for the new iTrack™ Advance. The team will now shift its focus to the broader market of cataract and anterior segment surgeons to drive greater growth. We will also leverage additional sales channels to place the device into the hands of adopting surgeons as quickly as possible."

“Whilst we are making good progress with the iTrack™ Advance in Germany and other markets, sales growth for the remainder of the 2023 fiscal year will be largely contingent on the timing of FDA U.S. 510(k) clearance of the iTrack™ Advance. In the meantime, our original iTrack™ canaloplasty product continues to achieve good sales momentum in the U.S.”

“Our performance in China during the period was significant, with the sustained marketing and sales effort of our local distribution partner delivering strong sales growth. The iTrack™ remains one of only two MIGS devices approved in China.”

The Company expects to release the audited half-year results for the period ending 31 December 2022 the week commencing 27 February 2023.

***This release dated 31 January 2023 has been authorised for lodgement to ASX by the Board of Directors of Nova Eye Medical Limited and lodged by Simon Gray, Company Secretary.***

– ENDS –

**Company**

Tom Spurling  
Managing Director  
+61 417 818 658  
[tspurling@nova-eye.com](mailto:tspurling@nova-eye.com)

**Company**

Kate Hunt  
Chief Commercial Officer  
+61 404 080 679  
[khunt@nova-eye.com](mailto:khunt@nova-eye.com)

**Investors**

Mark Flynn  
Investor Relations  
+61 416 068 733  
[mflynn@nova-eye.com](mailto:mflynn@nova-eye.com)

---

**ABOUT NOVA EYE MEDICAL**

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye’s natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of more

than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: [www.nova-eye.com](http://www.nova-eye.com)